Journal: Chemical & pharmaceutical bulletin

Article Title: Synthesis, Antiproliferative Activity and Molecular Docking Analysis of Both Enantiomerically Pure Decursin Derivatives as Anticancer Agents.

doi: 10.1248/cpb.c23-00718

Figure Lengend Snippet: Figure 2. Effects of decursin or (S)-2d (MRC-D-004) on the overexpression of CXCR7/ ACKR3, JAK1 & JAK2 activation and STAT3 activation in A549 lung cancer cells: (A) decursin or (S)-2d could not inhibit CXCR7/ACKR3 overexpression in A549 lung cancer cells regardless of their doses. (B) decursin or (S)-2d induced a decrease in p-JAK1 and p-STAT3 levels in A549 cells without effect on JAK1 and STAT3 proteins, while both compounds had no effect in JAK2 activation. (C) (S)-2d more strongly decreased in p-JAK1/JAK1 ratio than decursin at each 50 M concentration (D) (S)-2d more strongly decreased in p-STAT3/ STAT3 ratio than decursin at each 50 M concentration. Data are represented as mean ± SD of three experiments. Decursin and (S)-2d were compared with vehicle control by Student's t-test. ***P<0.001 vs. vehicle control.

Article Snippet: The blocked membranes were incubated with primary antibody for CXCR7 (PA3-069, 1:5000, Thermo Fisher Scientific, USA), GAPDH (5174, 1:1000, CST, USA), p-JAK1 (3331, 1:1000, CST, USA), JAK1 (3332, 1:1000, CST, USA), p-JAK2 (4406, 1:1000, CST, USA), JAK2 (3230, 1:1000, CST, USA), p-STAT3 (9145, Chemical and Pharmaceutical Bulletin Advance Publication 1:1000, CST, USA), STAT3 (4904, 1:1000, CST, USA), CDK2 (2546, 1:1000, CST, USA), Cyclin D1 (2978, 1:1000, CST, USA), Cyclin D3 (2936, 1:1000, CST, USA), p27 KIP1 (3686, 1:1000, CST, USA), p-cdc2 (4539, 1:1000, CST, USA), Cleaved caspase 8 (9496, 1:1000, CST, USA), Cleaved caspase 9 (7237, 1:1000, CST, USA) and PARP (9542, 1:1000, CST, USA) All primary antibodies were sued with overnight incubation at 4 °C.

Techniques: Over Expression, Activation Assay, Concentration Assay, Control